Aprea Therapeutics Stock Forum

$Aprea Therapeutics(APRE.US)$
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
Aprea Therapeutics has announced the dosing of the first patient in the ACESOT-1051 Phase 1 trial for their oral WEE1 inhibitor, APR-1051. This study is evaluating APR-1051 as a monotherapy for patients with advanced solid tumors who have unmet medical needs. APR-1051, developed by Aprea, targets the WEE1 kinase, an enzyme involved in the DNA dam...

$Aprea Therapeutics(APRE.US)$
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
Aprea Therapeutics announced that the Safety Review Committee (SRC) has approved dosing patients with ATRN-119 at 800 mg once daily in the ongoing ABOYA-119 clinical trial. ATRN-119, the first macrocyclic ATR inhibitor in clinic trials, has demonstrated a favorable safety profile through five dosage le...

$Aprea Therapeutics(APRE.US)$
NEWS
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Aprea Therapeutics, Inc. announces positive pre-clinical findings for APR-1051, a WEE1 kinase inhibitor, indicating potential as a treatment for Cyclin E-overexpressing cancers. The company also received IND clearance for APR-1051 and presented details on the planned Phase 1 trial. ATRN-119, a n...

$Aprea Therapeutics(APRE.US)$ Karolinska Development's Portfolio Company Aprea Therapeutics Receives FDA IND Approval and Secures Funding of USD 34 Million
GlobeNewswire· 4 mins ago

$Aprea Therapeutics(APRE.US)$ buy now

$Aprea Therapeutics(APRE.US)$ Watching closely for IND For ATRN-1051, it  is expected to be submitted this quarter

$Aprea Therapeutics(APRE.US)$ Positive Outlook for Aprea Therapeutics: Promising Developments and Safety Profile of ATRN-119 Bolster Buy Rating

$Aprea Therapeutics(APRE.US)$ Item 8.01Other Events.
On October 16, 2023, Aprea Therapeutics, Inc. issued a press release announcing initial clinical data on ATRi, ATRN-119, and pre-clinical data on WEE1i, ATRN-1051, presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, supporting highly differentiated synthetic lethality portfolio.  A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

$Aprea Therapeutics(APRE.US)$ Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors